Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Completed 6

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Sarcoma 1Other solid neoplasm 1CNS 1

Conditions

Carcinoma, Hepatocellular 2Solid Tumor 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Carcinosarcoma 1Camurati-Engelmann Syndrome 1

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × LY-2157299 × Clear all
NCT01582269 2025-11-24

A Study in Recurrent Glioblastoma (GB)

Eli Lilly and Company

Phase 2 Completed
158 enrolled 20 charts
CNS

Glioblastoma

NCT03206177 2024-08-07

Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

University of Oklahoma

Phase 1 Completed
26 enrolled 13 charts
Sarcoma

Carcinosarcoma

NCT02178358 2022-02-25

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
132 enrolled 25 charts
Gastrointestinal

Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

NCT02423343 2021-09-09

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Eli Lilly and Company

Phase 1/2 Completed
41 enrolled 21 charts
GastrointestinalOther solid neoplasmThoracic

Solid Tumor

NCT01246986 2021-01-12

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
204 enrolled 27 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01373164 2018-05-16

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Completed
170 enrolled 25 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡